clinical trial · NCT05009836
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Hutchison Medipharma Limited·phase3·active not recruiting·n = 320
Non-small Cell Lung CancerSavolitinibPlacebo
brief summary
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
started
Sep 6, 2021
primary completion
Aug 30, 2026
completion
Aug 30, 2026
last updated
Aug 29, 2025
detailed description
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
official title
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol